A partnership agreement has been signed by specialist antibody drug conjugate (ADC) contract services company, ADC Biotechnology, and multi-disciplined engineering specialists, WHP, for construction of a dedicated bioconjugation facility.
Construction
This construction agreement has followed the announcement in September that ADC Bio secured $11 million in funding to establish manufacturing operations for the supply of ADCs for human clinical trials. Construction has started at the company’s new site in Deeside, North Wales and is planned to be operational by September 2018.
“We are delighted to have forged this agreement with WHP. We specifically selected them as we found that their established reputation and industry recognition for high-quality design and construction of integrated systems and cleanroom technology — specifically within the biotechnology sector — made them the best fit for our needs,” stated Charlie Johnson, CEO of ADC Bio. “We look forward to a long-term relationship with them as we plan ahead and increase both capacity and our down-stream capabilities to meet the sectors significant growth forecasts.”
“These are exciting times for ADC Bio and WHP is thrilled to be supporting such a significant development milestone that will contribute ground-breaking solutions to human medicine,” added Ian Lichfield, CEO of WHP. “Our successful collaborations with Biotechnology companies and the wider Pharmaceuticals industry creates synergies with ADC Bio and adds value to the construction project. We look forward to a long and fruitful partnership with ADC Bio as the first stage of construction progresses to a second planned phase in 2019 in line with their strategy for expansion.”